Overall survival by different criteria in the training cohort (2 curves).

<p>Overall survival (OS) shown up to 72 months (mo) of all assessable patients by response criteria, divided in progressed versus not progressed (SD+PR) at 3, 6 and 12 months of imatinib therapy. To note, survival curves related to Choi criteria include only patients assessable with both manual and semi-automated method, thus they should be evaluated separately and not directly compared with the other criteria (Panels D,H,L). <b>Panels A–C:</b> When the tumor response is evaluated on the basis of RECIST and 3D criteria, a statistically significant difference is observed in the long-term prognosis between patients with and without PD at 3 months. <b>Panels E–G:</b> Significant difference is observed in the long-term prognosis between patients with and without PD at 6 months only by 3D-ellipsoids. <b>Panels I–K:</b> A difference is observed in the long-term prognosis between patients with and without PD at 12 months only by 3D-spheres and 3D-ellipsoids, but no significant difference is observed by RECIST. <b>Panels D,H,L:</b> Significant difference is observed in the long-term prognosis between patients with and without PD by Choi criteria only at 6 months.